Abstract
Hospitalization for heart failure (HF) is a clinical entity associated with high postdischarge morbidity and mortality, yet few therapies are available to improve outcomes in patients with this condition. In the past decade, large phase III studies of HF treatments have failed to demonstrate drug efficacy, safety, or both, despite encouraging results from preceding phase II trials. This Review is focused on this disconnect between the results of phase II and phase III trials of drugs for HF and discusses findings from five drug-development programs (for levosimendan, tezosentan, tolvaptan, rolofylline, and nesiritide) to shed light on common themes in clinical trials conducted in patients hospitalized for HF. In particular, the importance of selecting the 'right' patient population, drug, and clinical end points to optimize the trial design is discussed. Areas that require further investigation are highlighted and we suggest possible directions that will help to guide future clinical trials in these patients. Large, expensive phase III trials should not be initiated without adequate phase II evidence or on the basis of overly optimistic interpretation of phase II data. Additionally, drug development programs should be targeted not only to change short-term symptoms, but also to improve the postdischarge event rate.
Key Points
-
Patients hospitalized for heart failure (HF) are at a significantly high risk of postdischarge death or rehospitalization, despite conventional therapies
-
Large phase III clinical trials in patients hospitalized for HF have mainly provided negative results for primary safety or efficacy end points, despite encouraging results from preceding phase II studies
-
Inpatient surrogate end points such as dyspnoea relief might not correlate with postdischarge end points such as mortality and rehospitalization
-
Successful clinical trials require proper selection of the 'right' drug, target patient population, and end points
-
Analysis of five drug development programs (for levosimendan, tezosentan, tolvaptan, rolofylline, and nesiritide) will help to dissect the disconnect between phase II and phase III trials in patients hospitalized for HF
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Roger, V. L. et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125, e2–e220 (2012).
Jencks, S. F., Williams, M. V. & Coleman, E. A. Rehospitalizations among patients in the Medicare fee-for-service program. N. Engl. J. Med. 360, 1418–1428 (2009).
Chen, J., Normand, S. L., Wang, Y. & Krumholz, H. M. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA 306, 1669–1678 (2011).
Fonarow, G. C. et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J. Am. Coll. Cardiol. 50, 768–777 (2007).
Joynt, K. E. & Jha, A. K. Thirty-day readmissions—truth and consequences. N. Engl. J. Med. 366, 1366–1369 (2012).
Bueno, H. et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA 303, 2141–2147 (2010).
Curtis, L. H. et al. Early and long-term outcomes of heart failure in elderly persons, 2001–2005. Arch. Intern. Med. 168, 2481–2488 (2008).
Hunt, S. A. et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119, e391–e479 (2009).
Fonarow, G. C. et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 297, 61–70 (2007).
Gheorghiade, M. et al. Acute heart failure syndromes: current state and framework for future research. Circulation 112, 3958–3968 (2005).
Metra, M., Gheorghiade, M., Bonow, R. O. & Dei Cas, L. Postdischarge assessment after a heart failure hospitalization: the next step forward. Circulation 122, 1782–1785 (2010).
Gheorghiade, M. & Bonow, R. O. Heart failure: Early follow-up after hospitalization for heart failure. Nat. Rev. Cardiol. 7, 422–424 (2010).
Gheorghiade, M. et al. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail. Rev. 17, 485–509 (2012).
Felker, G. M. et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ. Heart Fail. 3, 314–325 (2010).
Gheorghiade, M. et al. Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am. Heart J. 157, 957–970 (2009).
O'Connor, C. M. et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am. Heart J. 159, 841–849.e1 (2010).
Joynt, K. E., Orav, E. J. & Jha, A. K. The association between hospital volume and processes, outcomes, and costs of care for congestive heart failure. Ann. Intern. Med. 154, 94–102 (2011).
Ross, J. S. et al. Recent national trends in readmission rates after heart failure hospitalization. Circ. Heart Fail. 3, 97–103 (2010).
Fonarow, G. C. et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J. Am. Coll. Cardiol. 50, 768–777 (2007).
Bhatia, R. S. et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 355, 260–269 (2006).
Gheorghiade, M., Teerlink, J. R. & Mebazaa, A. Pharmacology of new agents for acute heart failure syndromes. Am. J. Cardiol. 96, 68G–73G (2005).
Nieminen, M. S. et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J. Am. Coll. Cardiol. 36, 1903–1912 (2000).
Slawsky, M. T. et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 102, 2222–2227 (2000).
Moiseyev, V. S. et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur. Heart J. 23, 1422–1432 (2002).
Follath, F. et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360, 196–202 (2002).
Cleland, J. G., Freemantle, N., Coletta, A. P. & Clark, A. L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail. 8, 105–110 (2006).
Cleland, J. G. et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail. 6, 501–508 (2004).
Mebazaa, A. et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297, 1883–1891 (2007).
Aronson, D. & Burger, A. J. Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin. Pacing Clin. Electrophysiol. 26, 703–710 (2003).
Aronson, D. & Burger, A. J. Neurohormonal prediction of mortality following admission for decompensated heart failure. Am. J. Cardiol. 91, 245–248 (2003).
Coletta, A. P. & Cleland, J. G. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur. J. Heart Fail. 3, 747–750 (2001).
Torre-Amione, G. et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. 42, 140–147 (2003).
Kaluski, E. et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 41, 204–210 (2003).
O'Connor, C. M. et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J. Am. Coll. Cardiol. 41, 1452–1457 (2003).
Cotter, G. et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur. J. Heart Fail. 6, 601–609 (2004).
McMurray, J. J. et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298, 2009–2019 (2007).
Ghali, J. K., Hamad, B., Yasothan, U. & Kirkpatrick, P. Tolvaptan. Nat. Rev. Drug Discov. 8, 611–612 (2009).
Francis, G. S. et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82, 1724–1729 (1990).
Gheorghiade, M. et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291, 1963–1971 (2004).
Gheorghiade, M. et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297, 1332–1343 (2007).
Konstam, M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319–1331 (2007).
Udelson, J. E. et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J. Am. Coll. Cardiol. 52, 1540–1545 (2008).
Vallon, V., Muhlbauer, B. & Osswald, H. Adenosine and kidney function. Physiol. Rev. 86, 901–940 (2006).
Funaya, H. et al. Plasma adenosine levels increase in patients with chronic heart failure. Circulation 95, 1363–1365 (1997).
Forman, D. E. et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol. 43, 61–67 (2004).
Fonarow, G. C. et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293, 572–580 (2005).
Smith, G. L. et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J. Am. Coll. Cardiol. 47, 1987–1996 (2006).
Givertz, M. M. et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J. Am. Coll. Cardiol. 50, 1551–1560 (2007).
Dittrich, H. C. et al. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J. Card. Fail. 13, 609–617 (2007).
Cotter, G. et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J. Card. Fail. 14, 631–640 (2008).
Massie, B. M. et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 363, 1419–1428 (2010).
Abraham, W. T. et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J. Card. Fail. 4, 37–44 (1998).
Krum, H. & Liew, D. New and emerging drug therapies for the management of acute heart failure. Intern. Med. J. 33, 515–520 (2003).
Hobbs, R. E. et al. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 78, 896–901 (1996).
Marcus, L. S. et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 94, 3184–3189 (1996).
Mills, R. M. et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J. Am. Coll. Cardiol. 34, 155–162 (1999).
Colucci, W. S. et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. 343, 246–253 (2000).
Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287, 1531–1540 (2002).
Sackner-Bernstein, J. D., Kowalski, M., Fox, M. & Aaronson, K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293, 1900–1905 (2005).
Sackner-Bernstein, J. D., Skopicki, H. A. & Aaronson, K. D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111, 1487–1491 (2005).
O'Connor, C. M. et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365, 32–43 (2011).
Follath, F., Franco, F. & Cardoso, J. S. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am. J. Cardiol. 96, 80G–85G (2005).
Felker, G. M. et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J. Am. Coll. Cardiol. 41, 997–1003 (2003).
Gheorghiade, M. & Peterson, E. D. Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes. JAMA 305, 2456–2457 (2011).
Gheorghiade, M. & Ruschitzka, F. Beyond dyspnoea as an endpoint in acute heart failure trials. Eur. Heart J. 32, 1442–1445 (2011).
Mebazaa, A. et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur. Heart J. 31, 832–841 (2010).
Pang, P. S. et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur. Heart J. 29, 816–824 (2008).
Pang, P. S. et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur. Heart J. 30, 2233–2240 (2009).
Blair, J. E. et al. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur. Heart J. 30, 1666–1673 (2009).
Gheorghiade, M. et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296, 2217–2226 (2006).
Udelson, J. E. et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll. Cardiol. 49, 2151–2159 (2007).
Blair, J. E. et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur. Heart J. 32, 2563–2572 (2011).
Teerlink, J. R. et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373, 1429–1439 (2009).
Gheorghiade, M. & Pang, P. S. Acute heart failure syndromes. J. Am. Coll. Cardiol. 53, 557–573 (2009).
Adams, K. F. Jr et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 149, 209–216 (2005).
Cleland, J. G. et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur. Heart J. 24, 442–463 (2003).
Gheorghiade, M. et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur. J. Heart Fail. 14, 1056–1066 (2012).
Shin, D. D. et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am. J. Cardiol. 99, 4A–23A (2007).
Collins, S. P. et al. Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. Am. Heart J. 164, 138–145 (2012).
Author information
Authors and Affiliations
Contributions
M. Vaduganathan, S. J. Greene, and J. Butler wrote the article. All authors made substantial contributions to researching data for article, discussion of content, and reviewing and editing of manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
M. Gheorghiade declares that he has been a consultant for the following companies: Abbott, Astellas, AstraZeneca, Bayer, Corthera, Cytokinetics, Debiopharm, Errekappa Euroterapici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis, Otsuka, PDL Biopharma, PeriCor, Sanofi, Sigma-Tau, and Solvay Pharmaceuticals. J. Butler declares that he has been a consultant for Amgen, Bayer, CardioMEMS, Gambro, Ono Pharmaceutical, Takeda, and Trevena, and he has received research grants from GE Healthcare, Medtronic, National Heart Lung and Blood Institute, and National Institutes of Health. M. Vaduganathan, S. J. Greene, and A. P. Ambrosy declare no competing interests.
Rights and permissions
About this article
Cite this article
Vaduganathan, M., Greene, S., Ambrosy, A. et al. The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 10, 85–97 (2013). https://doi.org/10.1038/nrcardio.2012.181
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2012.181
This article is cited by
-
Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial
Nature Medicine (2021)
-
Endothelins in cardiovascular biology and therapeutics
Nature Reviews Cardiology (2019)
-
Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial
Cardiovascular Drugs and Therapy (2019)
-
Drugs’ development in acute heart failure: what went wrong?
Heart Failure Reviews (2018)
-
Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment
Current Heart Failure Reports (2018)